



Press release |

IBA TAKES A 25 % STAKE IN PET NET GERMANY AND REINFORCES GLOBAL PET RADIOPHARMACEUTICALS NETWORK

*Minority stake in PET Net gives IBA a basis for close partnership and larger capabilities in key market;
Global developer of next generation radiopharmaceuticals, IBA has the only worldwide network for
delivering personalized medicine PET solutions*

Louvain-la-Neuve, April 18, 2011 – Ion Beam Applications (IBA) S.A., global developer of next generation radiopharmaceuticals used in molecular imaging, announced today its minority stake acquisition in PET Net GmbH and PET Net Solutions AG (“PET Net”), providers of Positron Emission Tomography (PET) radiopharmaceuticals to nuclear medicine facilities throughout Germany. The addition of PET Net to IBA’s existing PET network—the largest in Europe and the only one on a global scale—reinforces IBA’s position as the leading global supplier of PET radiopharmaceuticals and provides the company with a local partner in Germany for developing and distributing future proprietary molecules.

Under the terms of the agreement, IBA has purchased 25.2% of PET Net from its owner, Medical Imaging Research Holding GmbH, in a cash transaction for a consideration between 2.5 million euro and 3 million euro. PET Net operates two profitable commercial GMP-certified PET sites located in Erlangen and Regensburg, Germany, has a European marketing authorization for FDG, a PET radiopharmaceutical used in oncology, and is a service provider for establishing PET production sites. IBA, long recognized as a leader in other areas in nuclear medicine including Single Photon Emission Computed Tomography (SPECT) and therapy through its German subsidiary CIS bio GmbH, will now have access to local PET infrastructure to build the foundation for an innovative PET offering and round out its nuclear medicine portfolio in Germany, a key radiopharmaceuticals market.

IBA has the only global PET network in the industry, with 57 PET facilities, and the most modern SPECT facility. These enable the company to manage direct distribution in the USA, Europe and India and deliver its products to 60 countries.

“IBA’s growth strategy has focused on expanding its manufacturing and distribution network in every major nuclear medicine market, and having a PET infrastructure in Germany was a critical element of this development,” said Pierre Mottet, chief executive officer of IBA. “IBA’s acquisition of shares in PET Net supports the uniqueness of our global network and brings the company one step closer to consolidating its position as market leader in next generation radiopharmaceuticals used in personalized medicine on a global scale.”

“PET Net and IBA share a joint mission, that of improving patient care,” said Professor Willi Kalender, founder and owner of PET Net. “I chose the name PET Net when founding the company in 1998 to make it clear from the start that a network is the goal. By partnering and joining complementing areas of expertise, we can facilitate this mission and develop novel proprietary molecules for the German radiopharmaceuticals market.”

PET is a non-invasive method used in molecular imaging to visualize biological processes for the early detection and real-time monitoring of diseases. By providing doctors with information about a body’s function as well as structure, diseases and their response to treatment can be imaged at a very early stage, which can lead to earlier, safer and more effective treatments. As PET radiopharmaceuticals must



Press release |

be delivered within a crucial window of time, IBA's unique network of facilities enables it to quickly supply safe and reliable solutions to nuclear medicine specialists across the globe.

About PET Net

PET Net GmbH was founded in 1998 by Prof. Dr. med. h.c. Willi Kalender, Ph.D. The production sites in Erlangen and Regensburg work closely with the University of Erlangen and the University hospital of Regensburg. PET Net's main interest is to develop and supply positron-emitting radiopharmaceuticals in Germany and its European neighbors. For more information, visit www.petnet-gmbh.de

About IBA

IBA group develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. The company is also active in the field of industrial sterilization and ionization, with decades of scientific expertise in health-related hygiene and safety. Its molecular imaging business unit develops, manufactures and distributes radiopharmaceutical products and supporting services on a global scale. With radiopharmaceutical development-to-delivery capabilities that address indications in neurology and Alzheimer's Disease detection, oncology and cellular death imaging and cardiology, in PET, SPECT and therapy, IBA has engineered a strong and unique product portfolio and pipeline of diagnostic tracers aimed at contributing to the development of the global trend towards personalized medicine and making molecular imaging a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs. IBA was awarded Frost & Sullivan's European Radiopharmaceuticals Technology Leadership of the Year prize in 2010.

Listed on the pan-European stock exchange EURONEXT, IBA group is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Please visit www.iba-worldwide.com for more information.

Contacts

PET Net

Erika Haschke

PET Net, Wetterkreuz 21, 91058 Erlangen

Tel: +49 9131 90867919

Erika.haschke@petnet-gmbh.de

IBA

Antoine Jacques

Marketing Europe

Tel: +33 1 69 85 76 65

antoine.jacques@iba-group.com

Media enquiries:

Christina Aplington

Tel: +33 1 42 22 24 10

christina@balloupr.com

Sandrine Leriche

Corporate communication

Tel: +32 10 47 58 90

sandrine.leriche@iba-group.com